FM101 Safety, Tolerability, Efficacy Study in the Patients With Ocular Hypertension

Summary

A PHASE 1/2A, RANDOMIZED, DOUBLE-MASKED, PLACEBO-CONTROLLED, MULTI-CENTER STUDY ASSESSING THE SAFETY, TOLERABILITY, AND EFFICACY OF FM101 IN PATIENTS WITH OCULAR HYPERTENSION, AND TO ASSESS THE RELATIVE BIOAVAILABILITY OF THE FM101 ORAL TABLET FORMULATION IN HEALTHY PARTICIPANTS

Timeline

Start

2020-10-07

Primary completion

2023-01-31

Completion

2023-06-30

Drugs

Indications